58 filings
Page 3 of 3
8-K
v4c36xi 5tsmk
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
fkcn7ztgjhmgbx
21 Mar 22
Departure of Directors or Certain Officers
6:32am
8-K/A
uwc4i2464o5mhs
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
s25wbedpj7pka
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
norz2d6589l
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
mub18z1w
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
24g60h34tnz54o8kdqxw
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
q2jj6lf0wj81
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
cxfm7r5
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
ubpwxtipsvmd9tb
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
ano7vv
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
bd1ck0 18f96
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
h2sk ldb0mjpnne3bcme
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
t74r3lft51gn
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
3v4avrkgy7
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
8-K
enl 49kh2k0592kg9n
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
talvns
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
8-K
7ko4gx
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
5:26pm